HAE
Clinical trials for HAE explained in plain language.
Never miss a new study
Get alerted when new HAE trials appear
Sign up with your email to follow new studies for HAE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Silencing the swelling: new drug aims to stop HAE attacks
Disease control Recruiting nowThis study tests a new medicine called ADX-324 for people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The drug uses a technology called siRNA to lower a protein involved in triggering attacks. About 90 adults with HAE type 1 or 2 wi…
Matched conditions: HAE
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 06:50 UTC
-
New hope for HAE patients: extension study tests long-term attack prevention
Disease control Recruiting nowThis study is for people with hereditary angioedema (HAE) who finished a previous phase 3 trial of ADX-324. It aims to see if the drug is safe and can prevent swelling attacks over a longer period. About 90 participants will receive additional doses of ADX-324 and be monitored fo…
Matched conditions: HAE
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New artery-blocking procedure aims to stop hemorrhoid bleeding without surgery
Symptom relief Recruiting nowThis study tests a procedure called hemorrhoidal artery embolization (HAE) for people with internal hemorrhoids who have not had success with other treatments or cannot have surgery. HAE blocks the blood supply to the hemorrhoid tissue to reduce symptoms, especially bleeding. Abo…
Matched conditions: HAE
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Symptom relief
Last updated May 04, 2026 16:18 UTC